Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series.

Butcher NJ, Boot E, Lang AE, Andrade D, Vorstman J, McDonald-McGinn D, Bassett AS.

Am J Med Genet A. 2018 May 19. doi: 10.1002/ajmg.a.38708. [Epub ahead of print]

PMID:
29777584
2.

Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2.

Boot E, Butcher NJ, Udow S, Marras C, Mok KY, Kaneko S, Barrett MJ, Prontera P, Berman BD, Masellis M, Dufournet B, Nguyen K, Charles P, Mutez E, Danaila T, Jacquette A, Colin O, Drapier S, Borg M, Fiksinski AM, Vergaelen E, Swillen A, Vogels A, Plate A, Perandones C, Gasser T, Clerinx K, Bourdain F, Mills K, Williams NM, Wood NW, Booij J, Lang AE, Bassett AS; International Research Group on 22q11.2DS-associated Parkinson's Disease.

Neurology. 2018 May 11. pii: 10.1212/WNL.0000000000005660. doi: 10.1212/WNL.0000000000005660. [Epub ahead of print]

PMID:
29752303
3.

Elucidating the diagnostic odyssey of 22q11.2 deletion syndrome.

Palmer LD, Butcher NJ, Boot E, Hodgkinson KA, Heung T, Chow EWC, Guna A, Crowley TB, Zackai E, McDonald-McGinn DM, Bassett AS.

Am J Med Genet A. 2018 Apr;176(4):936-944. doi: 10.1002/ajmg.a.38645.

PMID:
29575622
4.

Arylamine N-acetyltransferase 1 protects against reactive oxygen species during glucose starvation: Role in the regulation of p53 stability.

Wang L, Minchin RF, Butcher NJ.

PLoS One. 2018 Mar 8;13(3):e0193560. doi: 10.1371/journal.pone.0193560. eCollection 2018.

5.

22q11.2 deletion syndrome lowers seizure threshold in adult patients without epilepsy.

Wither RG, Borlot F, MacDonald A, Butcher NJ, Chow EWC, Bassett AS, Andrade DM.

Epilepsia. 2017 Jun;58(6):1095-1101. doi: 10.1111/epi.13748. Epub 2017 Apr 27.

PMID:
28448680
6.

Whole-genome sequencing suggests mechanisms for 22q11.2 deletion-associated Parkinson's disease.

Butcher NJ, Merico D, Zarrei M, Ogura L, Marshall CR, Chow EWC, Lang AE, Scherer SW, Bassett AS.

PLoS One. 2017 Apr 21;12(4):e0173944. doi: 10.1371/journal.pone.0173944. eCollection 2017.

7.

Sulfotransferase 1A3/4 copy number variation is associated with neurodegenerative disease.

Butcher NJ, Horne MK, Mellick GD, Fowler CJ, Masters CL; AIBL research group, Minchin RF.

Pharmacogenomics J. 2018 Apr;18(2):209-214. doi: 10.1038/tpj.2017.4. Epub 2017 Apr 4.

PMID:
28374858
8.

Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease.

Butcher NJ, Marras C, Pondal M, Rusjan P, Boot E, Christopher L, Repetto GM, Fritsch R, Chow EWC, Masellis M, Strafella AP, Lang AE, Bassett AS.

Brain. 2017 May 1;140(5):1371-1383. doi: 10.1093/brain/awx053.

PMID:
28369257
9.

Role for human arylamine N-acetyltransferase 1 in the methionine salvage pathway.

Witham KL, Minchin RF, Butcher NJ.

Biochem Pharmacol. 2017 Feb 1;125:93-100. doi: 10.1016/j.bcp.2016.11.015. Epub 2016 Nov 16.

PMID:
27865712
10.

Obesity in adults with 22q11.2 deletion syndrome.

Voll SL, Boot E, Butcher NJ, Cooper S, Heung T, Chow EW, Silversides CK, Bassett AS.

Genet Med. 2017 Feb;19(2):204-208. doi: 10.1038/gim.2016.98. Epub 2016 Aug 18.

11.

Drug delivery: Unravelling the stealth effect.

Butcher NJ, Mortimer GM, Minchin RF.

Nat Nanotechnol. 2016 Apr;11(4):310-1. doi: 10.1038/nnano.2016.6. Epub 2016 Feb 15. No abstract available.

PMID:
26878145
12.

Whole-Genome Sequencing Suggests Schizophrenia Risk Mechanisms in Humans with 22q11.2 Deletion Syndrome.

Merico D, Zarrei M, Costain G, Ogura L, Alipanahi B, Gazzellone MJ, Butcher NJ, Thiruvahindrapuram B, Nalpathamkalam T, Chow EW, Andrade DM, Frey BJ, Marshall CR, Scherer SW, Bassett AS.

G3 (Bethesda). 2015 Sep 16;5(11):2453-61. doi: 10.1534/g3.115.021345.

13.

Comparative mapping of the 22q11.2 deletion region and the potential of simple model organisms.

Guna A, Butcher NJ, Bassett AS.

J Neurodev Disord. 2015;7(1):18. doi: 10.1186/s11689-015-9113-x. Epub 2015 Jul 1.

14.

Pharmacological treatment of 22q11.2 deletion syndrome-related psychoses.

Boot E, Butcher NJ, Vorstman JA, van Amelsvoort TA, Fung WL, Bassett AS.

Pharmacopsychiatry. 2015 Sep;48(6):219-20. doi: 10.1055/s-0035-1554645. Epub 2015 Jun 19.

PMID:
26091278
15.

Fetal growth and gestational factors as predictors of schizophrenia in 22q11.2 deletion syndrome.

Van L, Butcher NJ, Costain G, Ogura L, Chow EW, Bassett AS.

Genet Med. 2016 Apr;18(4):350-5. doi: 10.1038/gim.2015.84. Epub 2015 Jun 18.

PMID:
26087175
16.

Response to clozapine in a clinically identifiable subtype of schizophrenia.

Butcher NJ, Fung WL, Fitzpatrick L, Guna A, Andrade DM, Lang AE, Chow EW, Bassett AS.

Br J Psychiatry. 2015 Jun;206(6):484-91. doi: 10.1192/bjp.bp.114.151837. Epub 2015 Mar 5.

17.

Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome.

Vorstman JA, Breetvelt EJ, Duijff SN, Eliez S, Schneider M, Jalbrzikowski M, Armando M, Vicari S, Shashi V, Hooper SR, Chow EW, Fung WL, Butcher NJ, Young DA, McDonald-McGinn DM, Vogels A, van Amelsvoort T, Gothelf D, Weinberger R, Weizman A, Klaassen PW, Koops S, Kates WR, Antshel KM, Simon TJ, Ousley OY, Swillen A, Gur RE, Bearden CE, Kahn RS, Bassett AS; International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome.

JAMA Psychiatry. 2015 Apr;72(4):377-85. doi: 10.1001/jamapsychiatry.2014.2671.

18.

Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome.

Boot E, Butcher NJ, van Amelsvoort TA, Lang AE, Marras C, Pondal M, Andrade DM, Fung WL, Bassett AS.

Am J Med Genet A. 2015 Mar;167A(3):639-45. doi: 10.1002/ajmg.a.36928. Epub 2015 Feb 13.

19.

The role of lysine(100) in the binding of acetylcoenzyme A to human arylamine N-acetyltransferase 1: implications for other acetyltransferases.

Minchin RF, Butcher NJ.

Biochem Pharmacol. 2015 Apr 1;94(3):195-202. doi: 10.1016/j.bcp.2015.01.015. Epub 2015 Feb 4.

PMID:
25660616
20.

Effects of human arylamine N-acetyltransferase I knockdown in triple-negative breast cancer cell lines.

Tiang JM, Butcher NJ, Minchin RF.

Cancer Med. 2015 Apr;4(4):565-74. doi: 10.1002/cam4.415. Epub 2015 Jan 28.

21.

Practical guidelines for managing adults with 22q11.2 deletion syndrome.

Fung WL, Butcher NJ, Costain G, Andrade DM, Boot E, Chow EW, Chung B, Cytrynbaum C, Faghfoury H, Fishman L, García-Miñaúr S, George S, Lang AE, Repetto G, Shugar A, Silversides C, Swillen A, van Amelsvoort T, McDonald-McGinn DM, Bassett AS.

Genet Med. 2015 Aug;17(8):599-609. doi: 10.1038/gim.2014.175. Epub 2015 Jan 8. Review.

22.

MicroRNA Dysregulation, Gene Networks, and Risk for Schizophrenia in 22q11.2 Deletion Syndrome.

Merico D, Costain G, Butcher NJ, Warnica W, Ogura L, Alfred SE, Brzustowicz LM, Bassett AS.

Front Neurol. 2014 Nov 21;5:238. doi: 10.3389/fneur.2014.00238. eCollection 2014.

23.

Expression of the orphan cytosolic sulfotransferase SULT4A1 and its major splice variant in human tissues and cells: dimerization, degradation and polyubiquitination.

Sidharthan NP, Butcher NJ, Mitchell DJ, Minchin RF.

PLoS One. 2014 Jul 2;9(7):e101520. doi: 10.1371/journal.pone.0101520. eCollection 2014.

24.

Cryptic epitopes of albumin determine mononuclear phagocyte system clearance of nanomaterials.

Mortimer GM, Butcher NJ, Musumeci AW, Deng ZJ, Martin DJ, Minchin RF.

ACS Nano. 2014 Apr 22;8(4):3357-66. doi: 10.1021/nn405830g. Epub 2014 Mar 27.

PMID:
24617595
25.

Interaction of human arylamine N-acetyltransferase 1 with different nanomaterials.

Deng ZJ, Butcher NJ, Mortimer GM, Jia Z, Monteiro MJ, Martin DJ, Minchin RF.

Drug Metab Dispos. 2014 Mar;42(3):377-83. doi: 10.1124/dmd.113.055988. Epub 2013 Dec 17.

26.

5-methyl-tetrahydrofolate and the S-adenosylmethionine cycle in C57BL/6J mouse tissues: gender differences and effects of arylamine N-acetyltransferase-1 deletion.

Witham KL, Butcher NJ, Sugamori KS, Brenneman D, Grant DM, Minchin RF.

PLoS One. 2013 Oct 25;8(10):e77923. doi: 10.1371/journal.pone.0077923. eCollection 2013.

27.

Cytosolic sulfotransferase 1A3 is induced by dopamine and protects neuronal cells from dopamine toxicity: role of D1 receptor-N-methyl-D-aspartate receptor coupling.

Sidharthan NP, Minchin RF, Butcher NJ.

J Biol Chem. 2013 Nov 29;288(48):34364-74. doi: 10.1074/jbc.M113.493239. Epub 2013 Oct 17.

28.

Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications.

Butcher NJ, Kiehl TR, Hazrati LN, Chow EW, Rogaeva E, Lang AE, Bassett AS.

JAMA Neurol. 2013 Nov;70(11):1359-66. doi: 10.1001/jamaneurol.2013.3646.

29.

Functional outcomes of adults with 22q11.2 deletion syndrome.

Butcher NJ, Chow EW, Costain G, Karas D, Ho A, Bassett AS.

Genet Med. 2012 Oct;14(10):836-43. doi: 10.1038/gim.2012.66. Epub 2012 Jun 28.

30.

Different classes of input and output neurons reveal new features in microglomeruli of the adult Drosophila mushroom body calyx.

Butcher NJ, Friedrich AB, Lu Z, Tanimoto H, Meinertzhagen IA.

J Comp Neurol. 2012 Jul 1;520(10):2185-201. doi: 10.1002/cne.23037.

PMID:
22237598
31.

Arylamine N-acetyltransferase 1: a novel drug target in cancer development.

Butcher NJ, Minchin RF.

Pharmacol Rev. 2012 Jan;64(1):147-65. doi: 10.1124/pr.110.004275. Epub 2011 Nov 16. Review.

32.

Biologically inspired EM image alignment and neural reconstruction.

Knowles-Barley S, Butcher NJ, Meinertzhagen IA, Armstrong JD.

Bioinformatics. 2011 Aug 15;27(16):2216-23. doi: 10.1093/bioinformatics/btr378. Epub 2011 Jul 8.

PMID:
21742636
33.

RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition.

Tiang JM, Butcher NJ, Cullinane C, Humbert PO, Minchin RF.

PLoS One. 2011 Feb 9;6(2):e17031. doi: 10.1371/journal.pone.0017031.

34.

Phosphorylation/dephosphorylation of human SULT4A1: role of Erk1 and PP2A.

Mitchell DJ, Butcher NJ, Minchin RF.

Biochim Biophys Acta. 2011 Jan;1813(1):231-7. doi: 10.1016/j.bbamcr.2010.09.011. Epub 2010 Oct 12.

35.

Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.

Paterson S, Sin KL, Tiang JM, Minchin RF, Butcher NJ.

Drug Metab Dispos. 2011 Jan;39(1):77-82. doi: 10.1124/dmd.110.036202. Epub 2010 Sep 24.

36.

Regulation of mouse brain-selective sulfotransferase sult4a1 by cAMP response element-binding protein and activating transcription factor-2.

Butcher NJ, Mitchell DJ, Burow R, Minchin RF.

Mol Pharmacol. 2010 Sep;78(3):503-10. doi: 10.1124/mol.110.063404. Epub 2010 Jun 22.

37.

Arylamine N-acetyltransferase 1 gene regulation by androgens requires a conserved heat shock element for heat shock factor-1.

Butcher NJ, Minchin RF.

Carcinogenesis. 2010 May;31(5):820-6. doi: 10.1093/carcin/bgq042. Epub 2010 Feb 22.

PMID:
20176657
38.

Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells.

Tiang JM, Butcher NJ, Minchin RF.

Biochem Biophys Res Commun. 2010 Feb 26;393(1):95-100. doi: 10.1016/j.bbrc.2010.01.087. Epub 2010 Jan 25.

PMID:
20100460
39.

Synaptic organization in the adult Drosophila mushroom body calyx.

Leiss F, Groh C, Butcher NJ, Meinertzhagen IA, Tavosanis G.

J Comp Neurol. 2009 Dec 20;517(6):808-24. doi: 10.1002/cne.22184.

PMID:
19844895
40.

Regulation of arylamine N-acetyltransferases.

Butcher NJ, Tiang J, Minchin RF.

Curr Drug Metab. 2008 Jul;9(6):498-504. Review.

PMID:
18680469
41.

Current trends in N-acetyltransferase research arising from the 2007 International NAT Workshop.

Boukouvala S, Westwood IM, Butcher NJ, Fakis G.

Pharmacogenomics. 2008 Jun;9(6):765-71. doi: 10.2217/14622416.9.6.765.

PMID:
18518853
42.

Polyamine-dependent regulation of spermidine-spermine N1-acetyltransferase mRNA translation.

Butcher NJ, Broadhurst GM, Minchin RF.

J Biol Chem. 2007 Sep 28;282(39):28530-9. Epub 2007 Aug 9.

43.

Arylamine N-acetyltransferase I.

Minchin RF, Hanna PE, Dupret JM, Wagner CR, Rodrigues-Lima F, Butcher NJ.

Int J Biochem Cell Biol. 2007;39(11):1999-2005. Epub 2007 Jan 20.

PMID:
17392017
44.

Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells.

Butcher NJ, Tetlow NL, Cheung C, Broadhurst GM, Minchin RF.

Cancer Res. 2007 Jan 1;67(1):85-92.

48.

Pharmacogenetics of the arylamine N-acetyltransferases.

Butcher NJ, Boukouvala S, Sim E, Minchin RF.

Pharmacogenomics J. 2002;2(1):30-42. Review.

PMID:
11990379
49.

Inactivation of human arylamine N-acetyltransferase 1 by the hydroxylamine of p-aminobenzoic acid.

Butcher NJ, Ilett KF, Minchin RF.

Biochem Pharmacol. 2000 Dec 15;60(12):1829-36.

PMID:
11108798
50.

Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells.

Butcher NJ, Ilett KF, Minchin RF.

Mol Pharmacol. 2000 Mar;57(3):468-73.

Supplemental Content

Loading ...
Support Center